Miromatrix Medical Inc. (MIRO) News

Miromatrix Medical Inc. (MIRO): $4.36

-0.03 (-0.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MIRO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 510

in industry

Filter MIRO News Items

MIRO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MIRO News Highlights

  • For MIRO, its 30 day story count is now at 3.
  • Over the past 16 days, the trend for MIRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about MIRO are ROSS, SAVE and STEM.

Latest MIRO News From Around the Web

Below are the latest news stories about MIROMATRIX MEDICAL INC that investors may wish to consider to help them evaluate MIRO as an investment opportunity.

Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event

EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particul

Yahoo | September 26, 2022

Miromatrix CEO Jeff Ross to Present at the Bioregate European Regenerative Medicine Forum

EDEN PRAIRIE, Minn., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Bioregate European Regenerative Medicine Forum. The conference, held this year on September 21-23 in Louvain-la-Neuve, Belgium, is dedicated to the 4R Medicine, Repair, Replacement, Regeneration, and Reprogrammi

Yahoo | September 20, 2022

Institutions own 18% of Miromatrix Medical Inc. (NASDAQ:MIRO) shares but individual investors control 52% of the company

To get a sense of who is truly in control of Miromatrix Medical Inc. ( NASDAQ:MIRO ), it is important to understand the...

Yahoo | September 10, 2022

Miromatrix Receives New Patent for Its Novel Perfusion Decellularization and Recellularization Technology

EDEN PRAIRIE, Minn., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, has received a new patent from the United States Patent and Trademark Office for its perfusion decellularization and recellularization technology. This new patent further expands the Company's extensive patent portfolio covering the bioengineering of transplanta

Yahoo | August 25, 2022

Miromatrix Announces Participation in Upcoming Gilmartin Emerging Growth Company Showcase

EDEN PRAIRIE, Minn., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the company will participate in the Gilmartin Emerging Growth Company Showcase on August 31st, 2022. Miromatrix’s management is scheduled to present at the Gilmartin Emerging Growth Company Showcase on Wednesday, August 31st, 2022 at 9:30 am

Yahoo | August 23, 2022

Miromatrix Reports Second Quarter 2022 Results and Provides Corporate Update

EDEN PRAIRIE, Minn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today reported second quarter 2022 financial results and provided a corporate update. "Each quarter, Miromatrix makes meaningful progress towards our goal of improving the lives of transplant patients with our bioengineered organs,” said Jeff Ross, Ph.D., Miroma

Yahoo | August 15, 2022

Miromatrix Appoints Jack Lake, M.D., as Medical Director

EDEN PRAIRIE, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, announced today that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medica

Yahoo | August 10, 2022

Miromatrix to Report Second Quarter 2022 Financial Results

EDEN PRAIRIE, Minn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time. Indiv

Yahoo | August 1, 2022

Axogen, Inc. Appoints William Burke to Board of Directors

Burke brings 25+ years of global financial leadership experience to the Axogen, Inc. Board of DirectorsALACHUA, Fla. and TAMPA, Fla., July 11, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that, effective July 11, 2022, William Burke has been appointed to its Board of Directors and will serve as chair of the Audit Committee. Mr. Burke is a recognized finance leader in

Yahoo | July 11, 2022

Miromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ Transplant

EDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, applauds the U.S. Food and Drug Administration (FDA) for hosting a two-day public advisory committee meeting to discuss scientific and regulatory topics relating to the field of organ transplant, specifically xenotransplantation. Opening remarks from the FDA hig

Yahoo | July 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5315 seconds.